FASEB J. Cell Migration Consortium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hellstrom, K. E.
Right arrow Articles by Hellstrom, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hellstrom, K. E.
Right arrow Articles by Hellstrom, I.

The FASEB Journal, Vol 3, 1715-1722, Copyright © 1989 by The Federation of American Societies for Experimental Biology

REVIEWS

Oncogene-associated tumor antigens as targets for immunotherapy

KE Hellstrom and I Hellstrom
ONCOGEN, Seattle, Washington 98104.

Cellular antigens encoded by tumor viruses and some antigens encoded by cellular oncogenes offer advantages as targets for immunotherapy by being inextricably associated with the neoplastic phenotype. For example, monoclonal antibodies (MAb) specific for an antigen encoded by the neu oncogene have a direct inhibitory effect on proliferation of antigen-positive tumor cells. Many of the oncogene-encoded cell surface molecules are growth factor receptors, as are some tumor-associated differentiation antigens (TADAs). Therefore, it is not surprising that their level of cancer specificity is similar. There have been some promising findings from using TADAs as targets for various forms of immunotherapy, and one would expect the results to further improve by targeting to molecules that are more directly involved in cell proliferation and/or in maintaining the malignant state.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Ohlen, M. Kalos, D. J. Hong, A. C. Shur, and P. D. Greenberg
Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen
J. Immunol., February 15, 2001; 166(4): 2863 - 2870.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
I Pastan and D FitzGerald
Recombinant toxins for cancer treatment
Science, November 22, 1991; 254(5035): 1173 - 1177.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by The Federation of American Societies for Experimental Biology.